Research in NSCLC is moving rapidly on two fronts: next-generation targeted therapiesDrugs that block specific molecules that cancer cells need to grow.Click for full explanation → and novel treatment combinations.
For KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12C, studies are comparing newer inhibitors, including divarasib and olomorasib, against the approved agents sotorasib and adagrasib, with the goal of improving efficacy and tolerability. A Phase 3 trial (CodeBreaK 202) is directly comparing sotorasib plus chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → against pembrolizumab plus chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → as first-line therapy in KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12C-positive NSCLC. Researchers are also investigating resistance mechanisms, with one study identifying that dysregulated efferocytosis, the process by which cells clear dead cell debris, drives resistance to both gefitinib and sotorasib independent of mutationA change in DNA sequence that can drive cancer development.Click for full explanation → type.
Interest is growing in KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12D, a different mutationA change in DNA sequence that can drive cancer development.Click for full explanation →. The investigational agent zoldonrasib showed an objective response rateThe proportion of patients whose cancer shrinks or disappears after treatment.Click for full explanation → of 52% and a median progression-free survival of 11.1 months in early Phase 1 results, suggesting activity in this previously harder-to-target subgroup.
Antibody-drug conjugates (ADCs) are another active area. Datopotamab deruxtecan, evaluated in the ICARUS-LUNG01 Phase 2 study, is being assessed in pretreated advanced NSCLC, with parallel work to identify biomarkersA measurable biological signal used to detect disease or predict treatment response.Click for full explanation → that predict who benefits most.
Personalized mRNA vaccines are entering Phase 3 evaluation. The INTerpath-009 trial is testing intismeran autogene, a personalized mRNA cancer vaccine, in combination with pembrolizumab and chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →. Serial liquid biopsy using plasma comprehensive genomic profiling is also being studied as a tool to detect resistance mutationsA change in DNA sequence that can drive cancer development.Click for full explanation → and guide treatment decisions after first-line progression.
Where the evidence stands
The treatment landscape for NSCLC spans a wide range of evidence stages. Several targeted therapiesDrugs that block specific molecules that cancer cells need to grow.Click for full explanation →, including osimertinib, lorlatinib, sotorasib, and adagrasib, are approved and in routine use. Multiple immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → agents are approved across different settings, from early-stage adjuvant use to metastatic disease.
In Phase 3 trials, next-generation KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12C inhibitors and new combination regimens, including ADC plus immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → combinations, are being evaluated against current standards. These are the closest to potential future approval.
Phase 2 data have established activity for ADCs like datopotamab deruxtecan, with confirmatory studies ongoing. Earlier Phase 1 work is exploring KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12D inhibitors, with zoldonrasib showing early promise, along with novel ADCs and small molecules targeting new pathways.
Personalized mRNA vaccines for lung cancer are in Phase 3, making them among the more advanced experimental approaches in oncology today.
What this means for people affected
Treatment options in lung cancer have expanded considerably, particularly for people whose tumors carry identifiable mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →. Molecular testing at diagnosis is now essential to determining the most appropriate available approach. Active research is extending targeted therapyDrugs that block specific molecules that cancer cells need to grow.Click for full explanation → to mutationsA change in DNA sequence that can drive cancer development.Click for full explanation → that were previously untreatable and working to improve outcomes for people who develop resistance to initial treatments. For those with no targetable mutationA change in DNA sequence that can drive cancer development.Click for full explanation → and low PD-L1 expression, immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →-chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → combinations remain standard, and several trials are testing strategies to improve on these results. The pace of change in this field is substantial, and clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → participation remains an important option for many people with advanced disease.
Last updated April 21, 2026
Recent research findings
Understanding evidence levels▼
PreclinicalLab or cell studies — no human data yet.
Animal StudyResults in animals only — may not apply to humans.
Phase 1 TrialFirst-in-human safety testing in small groups.
Phase 2 TrialEarly effectiveness testing in a larger group.
Phase 3 TrialLarge controlled trial — the strongest trial evidence.
Observational StudyPatterns observed in populations — not a controlled trial.
ReviewSummary analysis of multiple existing studies.
Meta-AnalysisStatistical pooling of results from multiple studies.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 21, 2026
Combining Colchicine and Rosiglitazone May Help Treat Lung Cancer
Researchers tested a combination of two drugs, colchicine and rosiglitazone, to see if it could help treat non-small cell lung cancer. They found that in some lab experiments, this combination worked better than either drug alone, but the results were different depending on the type of cancer cell. The study suggests that this combination may be a promising area for further research.
Why it matters: This finding could lead to new treatment options for patients with non-small cell lung cancer, particularly those with certain genetic mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →.
The study was conducted in lab experiments using two specific types of lung cancer cells, and the results may not apply to all patients with non-small cell lung cancer.
Phase 1/2 TrialCombined safety and early effectiveness trial in humans.Published: April 21, 2026
New Cancer Treatment Shows Promise for Lung Cancer Patients
Researchers tested a new medicine called elisrasib on patients with a specific type of lung cancer. They found that many patients had their disease under control after treatment. However, more research is needed to confirm these results.
Why it matters: This finding could lead to new treatment options for patients with this type of lung cancer.
Efficacy
Patients naïve to KRASG12C inhibitors experienced a disease control rate of 98.5%, while those refractory to other such drugs had a rate of 83.9%.
Phase 1/2 TrialCombined safety and early effectiveness trial in humans.Published: April 21, 2026
Amivantamab Shows Promise in Treating Advanced Colorectal Cancer
Researchers tested a new treatment called amivantamab in people with advanced colorectal cancer that didn't respond to other treatments. They found that amivantamab seemed to slow the growth of tumors in some patients, but more research is needed to confirm these results.
Why it matters: This finding could lead to new treatment options for people with advanced colorectal cancer who have run out of other choices.
Efficacy
The overall response rate was 29% in left-sided cohorts, and 22% in the right-sided cohort.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 21, 2026
KSR2 linked to resistance to cancer treatment
Researchers studied how cancer cells become resistant to a common treatment called anti-PD-1 therapy. They found that a protein called KSR2 might play a role in this resistance by changing how cancer cells use glucose. This could help explain why some cancer treatments don't work as well as they should.
Why it matters: This finding could help scientists understand why some cancer treatments don't work and identify new targets for treatment.
This study was conducted in a mouse model and may not directly apply to humans.
⚡ Major findingLater-stage evidence with especially strong reported efficacy, typically a phase 3 trial or meta-analysis.Phase 3 TrialLarge controlled trial comparing treatments. The strongest level of trial evidence.Published: April 20, 2026
Preoperative Exercise Program May Help Lung Surgery Patients Recover Faster
Researchers studied 120 patients with lung cancer who were about to undergo surgery. They found that a 7-day exercise program before surgery helped patients breathe better and exercise more strongly after surgery. However, the study was small and more research is needed to confirm these findings.
Why it matters: This finding could help doctors develop new strategies to support patients recovering from lung surgery.
Efficacy
The intervention group had significantly higher FEV1 (1.86 ± 0.64 vs. 1.55 ± 0.48 L, P = 0.003), FVC (2.30 ± 0.58 vs. 1.78 ± 0.42 L, P < 0.001), and PEF (4.50 ± 0.67 vs. 3.85 ± 0.64 L/s, P < 0.001) than the control group.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 20, 2026
Rare Lung Cancer Spread to Pleura Without Lymph Node Involvement
Researchers reported a case of lung cancer that spread to the pleura, a membrane surrounding the lungs, without any cancer cells found in nearby lymph nodes. This unusual case was identified during surgery. The cancer was found to have a specific genetic mutationA change in DNA sequence that can drive cancer development.Click for full explanation → called ALK rearrangement.
Why it matters: This finding highlights the importance of accurate staging and molecular testing in lung cancer diagnosis.
A single-case report, which may not be representative of all lung cancer patients.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 20, 2026
New Lung Cancer Dataset Aids Research into ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →
Researchers created a large dataset of lung cancer images to help develop new treatments. The dataset includes images from 155 patients with detailed annotations of tumor characteristics. This will aid in the development of algorithms to detect and analyze cancer cells.
Why it matters: This dataset will help scientists better understand lung cancer and develop more effective treatments.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 20, 2026
Galangin Sensitizes Lung Cancer Cells to Targeted TherapiesDrugs that block specific molecules that cancer cells need to grow.Click for full explanation →
Researchers identified a natural flavonoid called galangin that may help make lung cancer cells more sensitive to two targeted therapiesDrugs that block specific molecules that cancer cells need to grow.Click for full explanation →. In lab experiments, galangin restored tumor sensitivity to these therapies. The study suggests that galangin could be a useful tool for overcoming resistance to these treatments.
Why it matters: This finding could lead to new ways to treat lung cancer that has become resistant to current therapies.
This study was conducted in a lab setting and has not been tested in humans.
ReviewSummary and analysis of existing published studies.Published: April 20, 2026
New Approaches to Targeting KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation →MutationsA change in DNA sequence that can drive cancer development.Click for full explanation → in Lung Cancer
Researchers used a combination of computational and experimental methods to develop new treatments for non-small cell lung cancer caused by KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation →mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →. They explored ways to improve existing treatments and find new ones that can target multiple mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →. These methods included using artificial intelligence to identify potential compounds.
Why it matters: This research could lead to more effective treatments for patients with non-small cell lung cancer caused by KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation →mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →.
The review encompasses literature from 2013 to 2025, and the authors believe that artificial intelligence will eventually become standardized in drug discovery.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 20, 2026
Rare Cancer Complication in Lung Cancer Patients
Researchers treated a man with late-stage lung cancer using reduced doses of chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →. Despite precautions, the patient developed a rare and severe complication called tumour lysis syndrome. This condition can be life-threatening.
Why it matters: This finding highlights the importance of careful management when treating patients with critical airway obstruction and small cell lung cancer.
Phase 1 TrialFirst-in-human trial. Focuses on safety and dosing in small groups.Published: April 20, 2026
New Cancer Treatment Shows Promise in Lung Cancer Patients
Researchers tested a new cancer treatment called Sigvotatug Vedotin in patients with advanced lung cancer. They found that the treatment had some side effects but also showed promising results in shrinking tumors. More research is needed to confirm these findings.
Why it matters: This study provides early evidence that Sigvotatug Vedotin may be a useful treatment option for patients with advanced lung cancer.
Efficacy
The objective response rate was 19% and the median duration of response was 11.3 months in the overall population.
This study involved a small group of patients and was an early-stage trial.
✦ Significant findingA meaningful signal from later-stage research, or a strong phase 2 result that stands out from routine findings.Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Published: April 20, 2026
Combining Radiation and ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → Shows Promise for Lung Cancer
Researchers tested a combination of radiation and two immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → drugs in patients with advanced lung cancer. The treatment involved giving radiation to all cancer sites, followed by two immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → drugs every three weeks. After nine months, the researchers found that the treatment was effective for some patients, but more research is needed to confirm these results.
Why it matters: This study provides early evidence that combining radiation and immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → may be a promising approach for treating advanced lung cancer.
Efficacy
Median progression-free survival was 9.3 months (95% CI, 6.0-NR).
Testing the Addition of a Type of Drug Called ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → to the Usual ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
